GSK forms new deal with CureVac to make Covid variant vaccines
GSK strikes £132m deal with CureVac to develop vaccines for Covid variants as it reveals lacklustre annual results A total of £132m will be invested by GlaxoSmithKline into CureVac’s research Demand for GSK-made pain relief and digestive health products grew strongly GSK’s largest division, Pharmaceuticals, saw its sales drop 3% to £17.1bn By Harry Wise … Read more